A pharmaceutical composition for inhibiting eIF-2α phosphorylation to prevent and treat atherosclerosis

Background

Atherosclerosis is a chronic, progressive disease characterized by the buildup of fatty deposits, cholesterol, and cellular debris within the arterial walls, leading to the formation of plaques. This process is a major underlying cause of cardiovascular diseases such as heart attacks and strokes, which are leading causes of morbidity and mortality worldwide. The disease begins when low-density lipoproteins (LDL) and other ApoB-containing lipoproteins accumulate in the arterial intima, triggering an inflammatory response. Macrophages, a type of immune cell, engulf these lipoproteins and transform into foam cells, which are central to plaque development and progression. The persistence and growth of these plaques can eventually lead to arterial blockage or rupture, resulting in life-threatening events. Given the global health burden of atherosclerosis and its complications, there is a critical need for therapies that target the underlying cellular and molecular mechanisms driving plaque formation and progression.

Current therapeutic approaches to atherosclerosis primarily focus on lowering systemic lipid levels through lifestyle modification and pharmacological agents such as statins, fibrates, and cholesterol absorption inhibitors. While these treatments can reduce circulating cholesterol and slow disease progression, they do not directly address the intracellular processes within macrophages that lead to foam cell formation. Moreover, some patients experience insufficient response or adverse effects from existing lipid-lowering drugs. Importantly, the degradation of lipoproteins within macrophage lysosomes is often impaired due to reduced synthesis of lysosomal hydrolases, a problem that is not corrected by lowering plasma lipid levels alone. This impairment is linked to cellular stress pathways that inhibit protein synthesis, further exacerbating foam cell accumulation and plaque growth. As a result, there remains an unmet need for therapies that can restore lysosomal function and directly prevent the pathological transformation of macrophages in atherosclerosis.

Technology

This technology introduces a novel therapeutic strategy for treating atherosclerosis by targeting the molecular pathway responsible for foam cell formation within arterial walls. The approach centers on the administration of 2-aminopurine (2-AP) or its pharmaceutically acceptable salts, which act as inhibitors of eIF-2α kinase activity. By blocking the phosphorylation of eIF-2α, 2-AP restores the synthesis of lysosomal hydrolases in macrophages, thereby enhancing the degradation of lipoproteins that would otherwise accumulate and form foam cells—a key driver of atherosclerotic plaque development. The treatment can be formulated for various routes of administration, including oral, parenteral, and topical forms, and may be used in combination with established lipid-lowering agents such as statins or fibrates to maximize therapeutic benefits. Experimental evidence from animal models demonstrates that 2-AP significantly reduces atherosclerotic lesion size without altering systemic lipid, glucose, or insulin levels, indicating a direct effect on the pathological process within arterial macrophages.

What differentiates this technology is its unique mechanism of action, which intervenes upstream of traditional lipid-lowering therapies by directly addressing the cellular dysfunction that leads to foam cell formation. Unlike conventional treatments that primarily reduce circulating lipid levels, this approach restores the macrophage’s ability to degrade lipoproteins by preventing the suppression of lysosomal enzyme production—a process triggered by eIF-2α phosphorylation in response to lipoprotein accumulation. This targeted intervention not only reduces plaque formation but also avoids systemic metabolic disturbances, making it particularly suitable for patients with genetic predispositions such as ApoE polymorphisms. The versatility of 2-AP formulations and its compatibility with other antiatherogenic agents further enhance its clinical utility, offering a comprehensive and differentiated solution for managing atherosclerosis and related cardiovascular conditions.

Benefits

• Effectively reduces atherosclerotic lesion size by inhibiting eIF-2α phosphorylation in macrophages
• Restores lysosomal hydrolase synthesis, enhancing degradation of lipoproteins and preventing foam cell formation
• Acts directly on macrophage function without altering systemic lipid, glucose, or insulin levels
• Can be administered via multiple routes with flexible pharmaceutical formulations
• Supports combination therapy with existing lipid-lowering agents to enhance therapeutic efficacy
• Targets a key molecular mechanism underlying atherosclerosis progression, offering a novel treatment approach
• Potentially applicable to human patients with ApoE polymorphisms and other hyperlipidemic conditions

Applications

• Atherosclerosis therapeutic drug development
• Combination therapy with statins
• Treatment for ApoE polymorphism patients
• Veterinary cardiovascular disease management

Additional info

This therapeutic method addresses atherosclerosis by administering 2-aminopurine (2-AP). 2-AP inhibits eIF-2α kinase activity, reducing its phosphorylation. This restores lysosomal hydrolase synthesis, enhancing lipoprotein degradation within macrophage lysosomes. Consequently, it prevents lipoprotein accumulation and foam cell formation, thereby reducing atherosclerotic lesions. Formulations include various pharmaceutical compositions, optionally combined with other hypolipidemic agents.